Nqo1缺失抑制PI3K/Akt与MAPK/ERK通路并阻断肝细胞癌代谢适应
研究报道Nqo1在小鼠和人肝细胞癌中高表达,敲低Nqo1通过增强PP2A活性及诱导PTEN表达,同时抑制PI3K/Akt和MAPK/ERK通路,下调糖酵解和谷氨酰胺分解基因,阻断肝癌细胞代谢适应并抑制肿瘤生长。
要点
- Nqo1在小鼠和人肝细胞癌中高表达。
- 敲低Nqo1增强PP2A活性并诱导PTEN表达,抑制PI3K/Akt和MAPK/ERK通路。
- Nqo1缺失阻断代谢适应并抑制肝癌细胞增殖和小鼠HCC生长。
核心结论
- Nqo1作为PI3K/Akt和MAPK/ERK通路的上游激活因子,其缺失阻断代谢适应并抑制肝癌细胞增殖和小鼠HCC生长。
- 结果提示Nqo1可能作为抑制肝癌细胞增殖和HCC的治疗靶点。
研究设计与样本
- 研究采用小鼠和人肝细胞癌样本,检测Nqo1表达。
- 通过敲低和过表达Nqo1,分析PP2A活性、PTEN表达、PI3K/Akt和MAPK/ERK通路及代谢基因表达。
- 在小鼠中观察Nqo1缺失对HCC生长的影响。
主要发现
- Nqo1在小鼠和人肝细胞癌中强烈过表达。
- 敲低Nqo1增强丝氨酸/苏氨酸磷酸酶PP2A活性,使PDK1、Akt、Raf、MEK和ERK1/2去磷酸化并失活。
- Nqo1缺失通过ERK/CREB/c-Jun通路诱导PTEN表达,阻断PI3K/Akt信号。
- Nqo1缺失同时抑制PI3K/Akt和MAPK/ERK通路,下调糖酵解和谷氨酰胺分解基因,阻断肝癌细胞代谢适应。
- Nqo1过表达导致PI3K/Akt和MAPK/ERK通路过度激活并促进代谢适应。
临床怎么用
- Nqo1缺失可同时抑制PI3K/Akt和MAPK/ERK通路并阻断代谢适应。
- Nqo1可能作为抑制肝癌细胞增殖和HCC的治疗靶点。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Cancer cells undergo metabolic adaptation to sustain uncontrolled proliferation. Aerobic glycolysis and glutaminolysis are two of the most essential characteristics of cancer metabolic reprogramming. Hyperactivated phosphoinositide 3-kinase (PI3K)/Akt serine/threonine kinase (Akt) and mitogen-activated protein kinase (MAPK)/extracellular signal-regulated kinase (ERK) signaling pathways play central roles in cancer cell metabolic adaptation given that their downstream effectors, such as Akt and c-Myc, control most of the glycolytic and glutaminolysis genes. Here, we report that the cytosolic flavoprotein, NAD(P)H quinone dehydrogenase 1 (Nqo1), is strongly overexpressed in mouse and human hepatocellular carcinoma (HCC). Knockdown of Nqo1 enhanced activity of the serine/threonine phosphatase, protein phosphatase 2A, which operates at the intersection of the PI3K/Akt and MAPK/ERK pathways and dephosphorylates and inactivates pyruvate dehydrogenase kinase 1, Akt, Raf, mitogen-activated protein kinase kinase, and ERK1/2. Nqo1 ablation also induced the expression of phosphatase and tensin homolog, a dual protein/lipid phosphatase that blocks PI3K/Akt signaling, through the ERK/cAMP-responsive element-binding protein/c-Jun pathway. Together, Nqo1 ablation triggered simultaneous inhibition of the PI3K/Akt and MAPK/ERK pathways, suppressed the expression of glycolysis and glutaminolysis genes and blocked metabolic adaptation in liver cancer cells. Conversely, Nqo1 overexpression caused hyperactivation of the PI3K/Akt and MAPK/ERK pathways and promoted metabolic adaptation. Conclusion: In conclusion, Nqo1 functions as an upstream activator of both the PI3K/Akt and MAPK/ERK pathways in liver cancer cells, and Nqo1 ablation blocked metabolic adaptation and inhibited liver cancer cell proliferation and HCC growth in mice. Therefore, our results suggest that Nqo1 may function as a therapeutic target to inhibit liver cancer cell proliferation and inhibit HCC.
引用
- Dimri M, Humphries A, Laknaur A, et al. NAD(P)H Quinone Dehydrogenase 1 Ablation Inhibits Activation of the Phosphoinositide 3-Kinase/Akt Serine/Threonine Kinase and Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase Pathways and Blocks Metabolic Adaptation in Hepatocellular Carcinoma. Hepatology. 2019. PMID: 31215069. doi:10.1002/hep.30818
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。